TY - JOUR
T1 - Pre-clinical studies of epigenetic therapies targeting histone modifiers in lung cancer
AU - Huffman, Kenneth
AU - Martinez, Elisabeth D.
PY - 2013
Y1 - 2013
N2 - Treatment options for lung cancer patients have been generally limited to standard therapies or targeted interventions which involve a small number of known mutations. Although the targeted therapies are initially successful, they most often result in drug resistance, relapse, and mortality. We now know that the complexity of lung cancer comes not only from genomic changes, but also from aberrant epigenetic regulatory events. Epigenetic therapies have shown promise as single agents in the treatment of hematological malignancies but have yet to meet this expectation in solid tumors thus fostering researchers to pursue new approaches in the development and use of epigenetic interventions. Here, we review some recent pre-clinical findings involving the use of drugs targeting histone modifying enzymes both as single agents and as co-therapies against lung cancer. A greater understanding of the impact of these epigenetic compounds in lung cancer signaling is needed and further evaluation in vivo is warranted in several cases based on the pre-clinical activity of a subset of compounds discussed in this review, including drugs co-targeting HDACs and EGF receptor, targeting Brd4 and targeting Jumonji histone demethylases.
AB - Treatment options for lung cancer patients have been generally limited to standard therapies or targeted interventions which involve a small number of known mutations. Although the targeted therapies are initially successful, they most often result in drug resistance, relapse, and mortality. We now know that the complexity of lung cancer comes not only from genomic changes, but also from aberrant epigenetic regulatory events. Epigenetic therapies have shown promise as single agents in the treatment of hematological malignancies but have yet to meet this expectation in solid tumors thus fostering researchers to pursue new approaches in the development and use of epigenetic interventions. Here, we review some recent pre-clinical findings involving the use of drugs targeting histone modifying enzymes both as single agents and as co-therapies against lung cancer. A greater understanding of the impact of these epigenetic compounds in lung cancer signaling is needed and further evaluation in vivo is warranted in several cases based on the pre-clinical activity of a subset of compounds discussed in this review, including drugs co-targeting HDACs and EGF receptor, targeting Brd4 and targeting Jumonji histone demethylases.
KW - BRD4
KW - EZH2 inhibitors
KW - Epigenetic therapeutics
KW - HDAC inhibitors
KW - Jumonji demethylases
KW - Jumonji inhibitors
KW - Lung cancer
KW - Pre-clinical studies
UR - http://www.scopus.com/inward/record.url?scp=84891098436&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84891098436&partnerID=8YFLogxK
U2 - 10.3389/fonc.2013.00235
DO - 10.3389/fonc.2013.00235
M3 - Short survey
C2 - 24058902
AN - SCOPUS:84891098436
SN - 2234-943X
VL - 3 SEP
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - Article 235
ER -